Clinical trial
A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and…
NCT00434226 · Genentech, Inc., Industry · Terminated
Key facts
| NCT number | NCT00434226 |
|---|---|
| Title | A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L) |
| Official title | A Randomized, Controlled, Open-Label, Multicenter, Phase II Study of the Safety and Efficacy of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | bevacizumab, sunitinib, carboplatin, paclitaxel |
| Enrollment | 56 |
| Start date | Mar 1, 2007 |
| Primary completion | Apr 1, 2008 |
| First posted | Feb 13, 2007 |
| Last update posted | Aug 21, 2009 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: